Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary: Global Hereditary Angioedema Treatment Market


4. Market Overview

4.1. Introduction

4.1.1. Drug Class Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)


5. Market Outlook

5.1. Pipeline Analysis

5.2. Orphan Drug Exclusivity Scenario

5.3. Key Merger & Acquisitions

5.4. Disease Overview

5.5. Disease Prevalence-Global and Key Countries


6. Global Hereditary Angioedema Treatment Market Analysis and Forecast, by Drug Class, 2017–2027

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Class, 2017–2027

6.3.1. C1 Esterase Inhibitor

6.3.1.1. Plasma Products

6.3.1.1.1. Berinert

6.3.1.1.2. Cinryze

6.3.1.1.3. Haegarda

6.3.1.2. Recombinant Products

6.3.1.2.1. Ruconest

6.3.2. Selective Bradykinin B2 Receptor Antagonist

6.3.2.1. Firazyr

6.3.3. Kallikrein Inhibitor

6.3.3.1. Kalbitor

6.3.3.2. Takhzyro

6.3.4. Others

6.3.4.1. Conventional Drugs

6.3.4.2. Pipeline Drugs

6.4. Market Attractiveness By Drug Class


7. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Route of Administration, 2017–2027

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Route of Administration, 2017–2027

7.3.1. Intravenous

7.3.2. Subcutaneous Injection

7.3.3. Oral

7.4. Market Attractiveness, by Route of Administration


8. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Distribution Channel, 2017–2027

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Distribution Channel, 2017–2027

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. Market Attractiveness, by Distribution Channel


9. Global Hereditary Angioedema Treatment Market Analysis and Forecasts, by Region, 2017–2027

9.1. Key Findings

9.2. Market Value Forecast, by Region

9.2.1. North America

9.2.2. Europe

9.2.3. Rest of the World

9.3. Market Attractiveness, by Country/Region


10. North America Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Drug Class, 2017–2027

10.2.1. C1 Esterase Inhibitor

10.2.1.1. Plasma Products

10.2.1.1.1. Berinert

10.2.1.1.2. Cinryze

10.2.1.1.3. Haegarda

10.2.1.2. Recombinant Products

10.2.1.2.1. Ruconest

10.2.2. Selective Bradykinin B2 Receptor Antagonist

10.2.2.1. Firazyr

10.2.3. Kallikrein Inhibitor

10.2.3.1. Kalbitor

10.2.3.2. Takhzyro

10.2.4. Others

10.2.4.1. Conventional Drugs

10.2.4.2. Pipeline Drugs

10.3. Market Value Forecast, by Route of Administration, 2017–2027

10.3.1. Intravenous

10.3.2. Subcutaneous Injection

10.3.3. Oral

10.4. Market Value Forecast, by Distribution Channel, 2017–2027

10.4.1. Hospital Pharmacies

10.4.2. Retail Pharmacies

10.4.3. Others

10.5. Market Value Forecast, by Country, 2017–2027

10.5.1. U.S.

10.5.2. Canada

10.6. Market Attractiveness Analysis

10.6.1. By Drug Class

10.6.2. By Route of Administration

10.6.3. By Distribution Channel

10.6.4. By Country


11. Europe Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

11.1. .Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Drug Class, 2017–2027

11.2.1. C1 Esterase Inhibitor

11.2.1.1. Plasma Products

11.2.1.1.1. Berinert

11.2.1.1.2. Cinryze

11.2.1.1.3. Haegarda

11.2.1.2. Recombinant Products

11.2.1.2.1. Ruconest

11.2.2. Selective Bradykinin B2 Receptor Antagonist

11.2.2.1. Firazyr

11.2.3. Kallikrein Inhibitor

11.2.3.1. Kalbitor

11.2.3.2. Takhzyro

11.2.4. Others

11.2.4.1. Conventional Drugs

11.2.4.2. Pipeline Drugs

11.3. Market Value Forecast, by Route of Administration, 2017–2027

11.3.1. Intravenous

11.3.2. Subcutaneous Injection

11.3.3. Oral

11.4. Market Value Forecast, by Distribution Channel, 2017–2027

11.4.1. Hospital Pharmacies

11.4.2. Retail Pharmacies

11.4.3. Others

11.5. Market Value Forecast, by Country/Sub-region, 2017–2027

11.5.1. Germany

11.5.2. U.K.

11.5.3. France

11.5.4. Spain

11.5.5. Italy

11.5.6. Rest of Europe

11.6. Market Attractiveness Analysis

11.6.1. By Drug Class

11.6.2. By Route of Administration

11.6.3. By Distribution Channel

11.6.4. By Country/Sub-region

12. Rest of the World Hereditary Angioedema Treatment Market Analysis and Forecast, 2017–2027

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Class, 2017–2027

12.2.1. C1 Esterase Inhibitor

12.2.1.1. Plasma Products

12.2.1.1.1. Berinert

12.2.1.1.2. Cinryze

12.2.1.1.3. Haegarda

12.2.1.2. Recombinant Products

12.2.1.2.1. Ruconest

12.2.2. Selective Bradykinin B2 Receptor Antagonist

12.2.2.1. Firazyr

12.2.3. Kallikrein Inhibitor

12.2.3.1. Kalbitor

12.2.3.2. Takhzyro

12.2.4. Others

12.2.4.1. Conventional Drugs

12.2.4.2. Pipeline Drugs

12.3. Market Value Forecast, by Route of Administration, 2017–2027

12.3.1. Intravenous

12.3.2. Subcutaneous Injection

12.3.3. Oral

12.4. Market Value Forecast, by Distribution Channel, 2017–2027

12.4.1. Hospital Pharmacies

12.4.2. Retail Pharmacies

12.4.3. Others

12.5. Market Attractiveness Analysis

12.5.1. By Drug Class

12.5.2. By Route of Administration

12.5.3. By Distribution Channel

13. Competitive Landscape

13.1. Market Player - Competition Matrix (By Tier and Size of companies)

13.2. Market Share Analysis, by Company, 2018

13.3. Company Profiles

13.3.1. Shire plc (Takeda Pharmaceutical Company Limited)

13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.1.2. Company Financials

13.3.1.3. Growth Strategies

13.3.1.4. SWOT Analysis

13.3.2. CSL Limited

13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.2.2. Company Financials

13.3.2.3. Growth Strategies

13.3.2.4. SWOT Analysis

13.3.3. Pharming Group N.V.

13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.3.2. Company Financials

13.3.3.3. Growth Strategies

13.3.3.4. SWOT Analysis

13.3.4. Ionis Pharmaceuticals, Inc.

13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.4.2. Company Financials

13.3.4.3. Growth Strategies

13.3.4.4. SWOT Analysis

13.3.5. BioCryst Pharmaceuticals, Inc.

13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.5.2. Company Financials

13.3.5.3. Growth Strategies

13.3.5.4. SWOT Analysis

13.3.6. KalVista Pharmaceuticals Ltd.

13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.6.2. Company Financials

13.3.6.3. Growth Strategies

13.3.6.4. SWOT Analysis

13.3.7. Attune Pharmaceuticals

13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

13.3.7.2. Company Financials

13.3.7.3. Growth Strategies

13.3.7.4. SWOT Analysis



List of Figures



Figure 01: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Hereditary Angioedema Treatment Market Value Share, by Drug Class, 2018

Figure 04: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018

Figure 05: Global Hereditary Angioedema Treatment Market Value Share, by Distribution Channel, 2018

Figure 06: Global Hereditary Angioedema Treatment Market Value Share, by Route of Administration, 2018

Figure 07: Global Hereditary Angioedema Treatment Market - Key Drivers and Restraints

Figure 08: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by C1 Esterase Inhibitor, 2017–2027

Figure 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Selective Bradykinin B2 Receptor Antagonist, 2017–2027

Figure 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Kallikrein Inhibitor, 2017–2027

Figure 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 13: Global Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 14: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2017–2027

Figure 16: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous Injection, 2017–2027

Figure 17: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 18: Global Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 19: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 20: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 21: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 22: Global Hereditary Angioedema Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 23: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 24: Global Hereditary Angioedema Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 25: Global Hereditary Angioedema Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 26: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 27: North America Hereditary Angioedema Treatment Market Value Share, by Country, 2018 and 2027

Figure 28: North America Hereditary Angioedema Treatment Market Attractiveness, by Country, 2019–2027

Figure 29: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 30: North America Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 31: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 32: North America Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 33: North America Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 34: North America Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 35: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 36: Europe Hereditary Angioedema Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 37: Europe Hereditary Angioedema Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

Figure 38: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 39: Europe Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 40: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 41: Europe Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 42: Europe Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 43: Europe Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 44: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, 2019–2027

Figure 45: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 46: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Drug Class, 2019–2027

Figure 47: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 48: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Route of Administration, 2019–2027

Figure 49: Rest of the World Hereditary Angioedema Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 50: Rest of the World Hereditary Angioedema Treatment Market Attractiveness, by Distribution Channel, 2019–2027

Figure 51: Global Hereditary Angioedema Treatment Market Share Analysis, by Company (2018)

Figure 52: Shire plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017

Figure 53: Shire plc, Breakdown of Net Sales (%), by Geography, 2017

Figure 54: Shire plc, Breakdown of Net Sales (%), by Therapeutic areas, 2017

Figure 55: Shire plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017

Figure 56: CSL Behring, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 57: CSL Behring, Breakdown of Net Sales (%), by Geography, 2018

Figure 58: CSL Behring, Breakdown of Net Sales (%), by Product Division/Therapy, 2018

Figure 59: CSL Limited, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 60: Pharming Group NV, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 61: Pharming Group NV, Breakdown of Net Sales (%), by Geography, 2018

Figure 62: Pharming Group NV, Region-wise Breakdown of Net Sales (%), by Ruconest, 2018

Figure 63: Pharming Group NV, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 64: Ionis Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 65: Ionis Pharmaceuticals, Inc., Breakdown of Net Sales (%), by Business Segment, 2018

Figure 66: Ionis Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 67: BioCryst Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 68: BioCryst Pharmaceuticals, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 69: KalVista Pharmaceuticals Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 70: KalVista Pharmaceuticals Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018


List of Tables



Table 01: Pipeline Analysis, by Phase III

Table 02: Pipeline Analysis, by Phase II and Phase I

Table 03: Pipeline Analysis, by Preclinical Trial

Table 04: Orphan Drug Exclusivity

Table 05: Key Mergers & Acquisition in the Hereditary Angioedema Treatment Market

Table 06: Disease Overview by Type of HAE

Table 07: Reported and Estimated Cases of HAE, by Country

Table 08: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 09: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 10: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 11: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 12: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 13: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 14: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 15: Global Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 16: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 17: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 19: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 20: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 21: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 22: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 23: North America Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 24: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 25: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 26: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 27: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 28: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 29: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 30: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 31: Europe Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 32: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 33: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by C1 Esterase Inhibitor, 2017–2027

Table 34: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Plasma Products, 2017–2027

Table 35: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Kallikrein Inhibitor, 2017–2027

Table 36: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Others, 2017–2027

Table 37: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 38: Rest of the World Hereditary Angioedema Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027